OncRef

Clinical Trial: NCT05168566

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Teligene US
Information Provided By:Teligene US
Last Update Posted:2026-10-21

Study Overview

Brief Summary

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Official Title

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Sutetinib Maleate Capsule

Other Study ID Numbers

  • SZCT-2020-06

Start Date (Actual)

2022-09-01

Primary Completion Date (Estimated)

2027-12

Study Completion Date (Estimated)

2028-12

Enrollment (Estimated)

128

Study Type

Interventional

Phase

Phase 2